Achieve Life Sciences announced that the last study follow-up visit for the last subject enrolled in the Phase 2 ORCA-V1 trial has occurred. "We are excited to have reached this important milestone in the ORCA-V1 trial, bringing us one step closer to understanding the cessation potential of cytisinicline in users of nicotine e-cigarettes who desire to quit," stated John Bencich, Chief Executive Officer of Achieve. "We look forward to reporting topline results in the second quarter of this year from both the ORCA-V1 trial, and separately from ORCA-3, our second Phase 3 trial in smoking cessation."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ACHV:
- Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation
- Achieve Life Sciences Announces Presentation of the Phase 3 ORCA-2 Trial of Cytisinicline at Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting
- Achieve Life Sciences presents Phase 3 ORCA-2 trial data
- Achieve Life Sciences management to meet virtually with Oppenheimer
- Achieve Life Sciences doses last subject in Phase 2 ORCA-V1 trial
